Alfasigma has agreed to acquire a gastrointestinal medicine from GSK, marking a strategic step to strengthen its global specialty portfolio. The deal centres on a well established product used in digestive health, reinforcing Alfasigma’s long standing focus in this therapeutic area.

The acquisition supports the Italian company’s ambition to grow internationally, particularly in markets where gastrointestinal disorders remain underdiagnosed and undertreated. By integrating the brand into its portfolio, Alfasigma aims to leverage its commercial infrastructure and scientific expertise to maximise the product’s potential.

For GSK, the transaction reflects its ongoing strategy to streamline its portfolio and focus on core therapeutic areas with higher growth potential. Divesting non core assets allows the company to prioritise innovation driven pipelines and vaccines.

Alfasigma expects the addition to generate stable revenues while enhancing its presence across Europe and beyond. The move also highlights continued deal activity in the pharma sector, as companies rebalance portfolios and pursue targeted growth opportunities.